Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study GlobeNewswire December 22, 2025 Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levels Dose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable safety profile Substantial reduction in […]

Getty Realty Corp. Announces 2025 Getty Gives Activity GlobeNewswire December 22, 2025 NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) — As part of its ongoing commitment to responsible corporate citizenship, Getty Realty Corp. (NYSE: GTY) (“Getty” or the “Company”), a net lease REIT focused on convenience and automotive retail real estate, announced today the results

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement GlobeNewswire December 22, 2025 JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension

Pilot challenges OTAs with launch of in-app booking GlobeNewswire December 22, 2025 Pilot the free Trip Planner, Itinerary & Booking App for Travel gives over 40,000 users access to “Stays” feature making travel planning within the discovery tool even more all encompassing. This is yet another challenge to the “status-quo” of online travel agencies. VANCOUVER,

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess(R) in Extremity Trauma Repair GlobeNewswire December 22, 2025 – Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) – – After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures –

EMulate Therapeutics, Inc. Announces Peer-Reviewed Publication Demonstrating its Paclitaxel ulRFE(R) Signal to Extend Survival and Slow Tumor Growth in Diffuse Midline Glioma Animal Model New study published in Journal of Electromagnetic Biology and Medicine provides additional validation for Company's technology and business model GlobeNewswire December 22, 2025 Bellevue, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) —

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer GlobeNewswire December 22, 2025 Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapy ALPACCA pivotal trial is designed to

Gabelli Global Financial Services Fund (GFSIX) Surpasses $100M in Assets GlobeNewswire December 22, 2025 GREENWICH, Conn., Dec. 22, 2025 (GLOBE NEWSWIRE) — The Gabelli Global Financial Services Fund (GFSIX) has surpassed $100M in assets under management (AUM), reflecting increasing investor participation and strong fund performance. Since its inception in 2018, GFSIX has been managed by

Statement on new EU choline chloride anti-dumping measures EU producers laud EU for addressing choline chloride dumping by China; measures will help preserve jobs and secure feed supply chain GlobeNewswire December 22, 2025 MONTVALE, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) — As producers of choline chloride in the EU, Eastman and Balchem welcome the European

CoRegen Appoints Globally Recognized Surgeon-Scientist Bert O'Malley Jr. to its Board of Directors GlobeNewswire December 22, 2025 HOUSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) — CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of solid tumor cancer, today announced the appointment of Bert W. O'Malley, Jr.,